Durability of Response to B‐Cell Maturation Antigen‐Directed mRNA Cell Therapy in Myasthenia Gravis

Documenti analoghi

• ADAPT NXT: Fixed Cycles or Every‐Other‐Week IV Efgartigimod in Generalized Myasthenia Gravis
  di: Ali A. Habib, et al.
  Pubblicazione: (2025)
• In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis
  di: Lei Jin, et al.
  Pubblicazione: (2025)
• Remote Monitoring in Myasthenia Gravis: Exploring Symptom Variability
  di: Maike Stein, et al.
  Pubblicazione: (2025)
• Correction to “Efgartigimod for Generalized Myasthenia Gravis: A Multicenter Real‐World Cohort Study in China”
  Pubblicazione: (2025)
• Prediction of Myasthenia Gravis Worsening: A Machine Learning Algorithm Using Wearables and Patient‐Reported Measures
  di: Maike Stein, et al.
  Pubblicazione: (2025)